Here are the 10-K annual reports from Solid Biosciences Inc. (SLDB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences is a gene therapy company focused on rare neuromuscular and cardiac diseases. Its lead program, SGT-003 for Duchenne muscular dystrophy, is in a Phase 1/2 trial with generally well-tolerated dosing in 41 participants and strong microdystrophin expression and biomarker improvements. A global Phase 3 trial in ambulant boys aged 7 to under 12 is starting, with potential accelerated approval discussions planned.
The company is also advancing SGT-212 for Friedreich’s ataxia in a Phase 1b dual-route (brain and IV) study, and SGT-501 for catecholaminergic polymorphic ventricular tachycardia in a Phase 1b trial. Preclinical cardiac candidate SGT-601 targets TNNT2-mediated dilated cardiomyopathy. Solid is building a broad platform around its POLARIS‑101 capsid, next‑generation capsid libraries, and manufacturing partnerships, supported by multiple licenses and collaborations with leading academic centers.